We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Surgery Should Be Primary Treatment for Achalasia

By HospiMedica International staff writers
Posted on 22 Aug 2012
Surgery should be the primary treatment for patients with achalasia, despite higher morbidity than observed with endoscopy, according to a new study.

Researchers at the University of Chicago (IL, USA) conducted a retrospective study in which they analyzed electronic medical records (EMRs) from 148 patients with achalasia between January 1, 2000, and August 9, 2011, to determine the efficacy of endoscopic versus surgical treatments. More...
In the surgical group, 72 patients underwent surgical myotomy with or without a full or partial fundoplication. Eight of those patients (11%) had more than one surgical admission, and 23 patients (32%) had undergone prior endoscopic treatment.

In the endoscopic group, 76 patients underwent only endoscopic treatments, which included balloon dilation, botulinum injection or both; 53 of those patients (70%) had more than one treatment, which came to 174 endoscopic interventions total. The investigators noted no statistically significant differences between the demographics, except that patients in the surgical cohort were significantly younger (56.3 versus 72.7 years).

The results showed that the average time between the first and second surgery was almost seven times longer than that for endoscopic procedures. Patients in the endoscopic group underwent a mean of three interventions and had significantly more dysphagia and gastroesophageal reflux disease (GERD)-related symptoms than the surgical group. The 30-day morbidity rate in the surgical group, however, was more than four times greater than that in the endoscopy group (6.9% versus 1.3% patients, respectively); deaths did not occur in either group. The study was presented at Digestive Disease Week (DDW), held during May 2012 in San Diego (CA, USA).

“Surgery is more efficacious than endoscopy alone because there is better resolution of achalasia and maybe even better treatment of the reflux,” said study investigator Michael Ujiki, MD, a clinical assistant professor of surgery. “If you look at this issue overall, the endoscopic surgeries end up costing more because of all the subsequent repeat interventions that may be required.”

Achalasia is an esophageal motility disorder involving the smooth muscle layer of the esophagus and the lower esophageal sphincter (LES). It is characterized by incomplete LES relaxation, increased LES tone, and lack of peristalsis of the esophagus. Achalasia is characterized by difficulty swallowing, regurgitation, and sometimes chest pain. Various treatments are available, although none cures the condition. Certain medications or Botox may be used in some cases, but more permanent relief is brought by esophageal dilatation and surgical cleaving of the muscle.

Related Links:

University of Chicago




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.